In two phase 3 , double-blind , 52-week trials , ERASURE ( Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis ) and FIXTURE ( Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis ) , we randomly assigned 738 patients ( in the ERASURE study ) and 1306 patients ( in the FIXTURE study ) to subcutaneous secukinumab at a dose of 300 mg or 150 mg ( administered once weekly for 5 weeks , then every 4 weeks ) , placebo , or ( in the FIXTURE study only ) etanercept at a dose of 50 mg ( administered twice weekly for 12 weeks , then once weekly ) .